Biotech Values

[genisi]

Paragraph IV filed in 2008 against the 2019 US patents not the 2015 COM patent, so clearly a final approval will only occur after expiration of the 2015 patent.
On a side note, Novartis is conducting a long litigation in India where Gleevec was not granted patent protection (total different situation there. For more readings: http://www.economist.com/node/21562226 ), but no suit against Sun Pharma in the US yet.